TriOptima tears up $720 billion of Delphi-related CDS

In the wake of Delphi’s filing for Chapter 11 bankruptcy protection on October 8, 21 dealers used the firm’s multilateral tear-up technology to terminate some 5,300 single-name Delphi CDS contracts with a notional value of $23 billion – approximately 70% of all outstanding Delphi single-name contracts – on October 12 and 19. Before bankruptcy, only about 500 Delphi CDS contracts had been terminated in regular tear-up cycles.

The Swedish firm also scheduled a special index termination cycle for October 20, having completed a regular index termination cycle on October 7. A total of 17,344 Delphi-affected index swaps with a notional value of almost $700 billion was torn up.

TriOptima’s tear-up technology allows swaps counterparties to multilaterally eliminate unnecessary trades from their books while allowing them to maintain the same net position in regular termination cycles. But targeting contracts where there has been a credit event also allows participants to eliminate many of the legal and administrative burdens involved in the settlement of a defaulted name.

Since the beginning of the year, TriOptima has terminated over 100,000 CDS contracts with a notional value of $2.3 trillion.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Next-generation technologies and the future of trading

At a Risk.net webinar in association with capital markets technology provider Numerix, panellists discuss the potential for increased adoption of the public cloud to boost investment performance, its impact on risk management and overcoming barriers to…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here